AI English summary of an SEC filing — figures as filed
Procter & Gamble PGProcter & Gamble said net sales for the 9 months ended March 31, 2025 were $63.4 billion, a decrease of $112 million versus the prior year period, and net earnings were $12.4 billion, an increase of $609 million, or 5%. Diluted EPS increased 6% to $5.03.
Key points
AI summaryProcter & Gamble said net sales for the 9 months ended March 31, 2025 were $63.4 billion, a decrease of $112 million versus the prior year period, and net earnings were $12.4 billion, an increase of $609 million, or 5%. Diluted EPS increased 6% to $5.03.
The company cited the prior year non-cash impairment charge on the Gillette intangible asset of $1.3 billion ($1.0 billion after tax) as a factor in the 9-month net earnings increase, and added that the current period reflected higher restructuring charges of $0.8 billion after tax related to the substantial liquidation of operations in Argentina.
The company said net sales for the quarter ended March 31, 2025 decreased 2% to $19.8 billion, with unfavorable foreign exchange of 2% and unit volume decline of 1% partially offset by higher pricing of 1%. Gross margin for the same quarter declined 20 basis points to 51.0%.
The company said operating cash flow for the 9 months ended March 31, 2025 was $12.8 billion, a decrease of $1.3 billion versus the prior year period. Adjusted free cash flow was $10.6 billion, and adjusted free cash flow productivity was 80%.
Key figures
Quarter ended March 31, 2025
- Revenue
- $19.8B
- Operating income
- $4.6B
- Net income
- $3.8B
- EPS
- $1.54
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
9-Month Net Sales, Net Earnings and Diluted EPS
Procter & Gamble said net sales for the 9 months ended March 31, 2025 were $63.4 billion, a decrease of $112 million versus the prior year period, and net earnings were $12.4 billion, an increase of $609 million, or 5%. Diluted EPS increased 6% to $5.03.
Source · Based on the MD&A text of the filing
Gillette Impairment Charge and Argentina Restructuring Costs
The company cited the prior year non-cash impairment charge on the Gillette intangible asset of $1.3 billion ($1.0 billion after tax) as a factor in the 9-month net earnings increase, and added that the current period reflected higher restructuring charges of $0.8 billion after tax related to the substantial liquidation of operations in Argentina.
Source · Based on the MD&A text of the filing
Quarterly Net Sales Change Drivers and Gross Margin
The company said net sales for the quarter ended March 31, 2025 decreased 2% to $19.8 billion, with unfavorable foreign exchange of 2% and unit volume decline of 1% partially offset by higher pricing of 1%. Gross margin for the same quarter declined 20 basis points to 51.0%.
Source · Based on the MD&A text of the filing
9-Month Operating Cash Flow and Adjusted Free Cash Flow
The company said operating cash flow for the 9 months ended March 31, 2025 was $12.8 billion, a decrease of $1.3 billion versus the prior year period. Adjusted free cash flow was $10.6 billion, and adjusted free cash flow productivity was 80%.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…